Medinol calls Boston boardroom ploy "absurd"
This article was originally published in Clinica
Medinol has reacted angrily to the request from Boston Scientific that it should get a board seat on the Israeli company. Boston is fighting in the courts for control of its stent supplier in which it has a 22% share. Now the issue is in the courts both in the US and in Israel and Medinol called Boston's move "absurd".